Gilead Sciences | Betriebsaufwand



Operating Expenses Veränderung Datum
AbbVie USD 9.71B 96M 2025-06
Agios Pharmaceuticals USD 139.51M 24.16M 2025-06
ALKERMES USD 297.68M 4.96M 2025-06
Alnylam Pharmaceuticals USD 789.89M 213.78M 2025-06
Amgen USD 6.52B 337M 2025-06
Biogen USD 1.79B 326.1M 2025-06
BioMarin Pharmaceutical USD 548.52M 27.27M 2025-06
Bristol-Myers Squibb USD 8.5B 265M 2025-06
Eli Lilly USD 8.54B 1.22B 2025-06
Gilead Sciences USD 4.35B 80M 2025-06
GlaxoSmithKline GBP 5.96B 663M 2025-06
Glaxosmithkline GBP 7.42B 408M 2024-12
Incyte USD 904.7M 56.97M 2025-06
J&J USD 16.8B 8.54B 2025-06
Merck USD 9.44B 217M 2025-06
Moderna USD 1.04B 113M 2025-06
Neurocrine Biosciences USD 541.9M 7M 2025-06
Novartis USD 9.97B 1.02B 2025-06
Pfizer USD 11.62B 1.58B 2025-06
PTC Therapeutics USD 213.73M 7.86M 2025-06
Regeneron Pharmaceuticals USD 2.6B 159.1M 2025-06
Sanofi EUR 9.02B 702M 2025-06
Sarepta Therapeutics USD 495.51M 549.73M 2025-06
United Therapeutics USD 521.7M 110.1M 2025-06
Vertex Pharmaceuticals USD 1.81B 71.4M 2025-06


Gilead Sciences Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Aug 2025.